Denosumab

Denosumab Struktur
615258-40-7
CAS-Nr.
615258-40-7
Englisch Name:
Denosumab
Synonyma:
D03684;AMG 162;Denosumab;Denosumab (usan);Denosumab (anti-TNFSF11);Denosumab (usan) USP/EP/BP;Research Grade Denosumab (DHA30301);IMMunoglobulin G2, anti-(huMan osteoclast differentiation factor) (huMan Monoclonal AMG162 heavy chain), disulfide with huMan Monoclonal AMG162 light chain, diMer;Denosumab,Immunoglobulin G2,Nuclear factor-kappaB,NF-κB,Immunoglobulin G-2,RANKL,Inhibitor,Ranmark,inhibit,Cancer,Immunoglobulin G 2,Osteoporosis,Nuclear factor-κB
CBNumber:
CB82493606
Summenformel:
C6404H9912N1724O2004S50
Molgewicht:
0
MOL-Datei:
Mol file

Denosumab Eigenschaften

Sicherheit

Denosumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Denosumab, which was approved in the United States in 2010, is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL). RANKL is a TNF family protein that is expressed in both secreted and cell surface forms by a variety of bone marrow cell types andmediates bone resorption through its receptor (RANK),which is found on osteoclasts and osteoclast precursors . Denosumab was discovered using XenomouseTM transgenic mice comprising human immunoglobulin genes. The antibody is approved for treatment of postmenopausal women with osteoporosis at high risk for fracture, and for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Denosumab competes directly with bisphosphonates such as alendronic acid in postmenopausal osteoporosis and with zoledronic acid in both of these indications. It has been shown to have comparable efficacy and safety to bisphosphonates with some tolerability and patient acceptability advantages.

Verwenden

Prevention and treatment of all forms of osteoporosis or bone loss.

Indications

  1. Prevention of skeletal-related events (e.g., bone pain and fractures) secondary to multiple myeloma or bone metastases from solid tumors. Used in conjunction with treatments for primary malignancy.
  2. Giant cell tumor of the bone. Indicated in adults and skeletally mature adolescents with an unresectable tumor or when surgical resection would likely cause severe morbidity.
  3. Hypercalcemia of malignancy. This drug is indicated when hypercalcemia is refractory to bisphosphonate therapy.
  4. Osteoporosis. Indicated as therapy for postmenopausal women with osteoporosis at high risk for fracture. Indications also include the treatment of men with osteoporosis at high risk of fracture. A high risk for fracture is defined as those with multiple risk factors for fracture, a known history of an osteoporotic fracture, or those who have failed prior osteoporosis treatment (e.g., bisphosphonates).
  5. Glucocorticoid-induced osteoporosis. Indicated for treatment in patients of both sexes at high risk for fracture who are initiating or continuing systemic glucocorticoids at a dose greater than or equal to 7.5 mg of prednisone daily for an expected duration of at least six months.
  6. Bone loss. Indicated for treating androgen deprivation-induced bone loss and aromatase inhibitor-induced bone loss. The goal of therapy is to increase bone mass in men with prostate cancer receiving androgen deprivation therapy. In women, the treatment goal is to increase bone mass when receiving aromatase inhibitor therapy for breast cancer.

Nebenwirkungen

  • red, dry, or itchy skin
  • oozing or crusty blisters on skin
  • peeling skin
  • back pain
  • pain in your arms
  • swelling of arms or legs
  • muscle or joint pain
  • nausea

Denosumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Denosumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 79)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shanghai Minbiotech Co., Ltd.
+8617315815539
sales@minbiotech.com CHINA 129 58
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 1000 58
Hubei xin bonus chemical co. LTD
86-13657291602
linda@hubeijusheng.com CHINA 22968 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569266 15319487004
1015@dideu.com China 2263 58
Hubei Ipure Biology Co., Ltd
+8613367258412
ada@ipurechemical.com China 10326 58
HONG KONG IPURE BIOLOGY CO.,LIMITED
86 18062405514 18062405514
ada@ipurechemical.com CHINA 3465 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 28251 58
AFINE CHEMICALS LIMITED
0571-85134551 18958018566;
info@afinechem.com China 15377 58
Baoji Guokang Healthchem co.,ltd
+8615604608665 15604608665
dominicguo@gk-bio.com CHINA 9427 58
Hefei Hirisun Pharmatech Co., Ltd
+8615056975894
shawn@hirisunpharm.com CHINA 9923 58

  • D03684
  • Denosumab
  • Denosumab (usan)
  • AMG 162
  • IMMunoglobulin G2, anti-(huMan osteoclast differentiation factor) (huMan Monoclonal AMG162 heavy chain), disulfide with huMan Monoclonal AMG162 light chain, diMer
  • Denosumab (usan) USP/EP/BP
  • Research Grade Denosumab (DHA30301)
  • Denosumab,Immunoglobulin G2,Nuclear factor-kappaB,NF-κB,Immunoglobulin G-2,RANKL,Inhibitor,Ranmark,inhibit,Cancer,Immunoglobulin G 2,Osteoporosis,Nuclear factor-κB
  • Denosumab (anti-TNFSF11)
  • 615258-40-7
  • C6404H9912N1724O2004S50
Copyright 2019 © ChemicalBook. All rights reserved